SCHEMBL290979

SCHEMBL290979

CCCCOC(=O)NOC(=O)C(O)Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.48
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
LMNA P02545 1/20 0.48
CTSK P43235 4/20 0.46
TDP1 Q9NUW8 3/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
TSHR P16473 2/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP3A4 P08684 1/20 0.46
MAPK1 P28482 1/20 0.46
GAA P10253 1/20 0.45
POLB P06746 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
ACE P12821 1/20 0.42
ACE2 Q9BYF1 1/20 0.42
HPGD P15428 1/20 0.42
CTSL P07711 1/20 0.42
CTSB P07858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL2946565 0.99 SMN1; SMN2 (0.47) SMN1; SMN2NPC1RAB9ALMNACTSK
SCHEMBL2426331 0.84 TSHR (0.54) SMN1; SMN2NPC1RAB9ALMNACTSK
SCHEMBL5668365 0.80 TSHR (0.53) SMN1; SMN2NPC1RAB9ALMNATDP1
SCHEMBL15094453 0.80 NAAA (0.47) CTSKALDH1A1POLBHPGDCTSL
SCHEMBL5994752 0.80 SRR (0.47) NPC1RAB9ACYP1A2
SCHEMBL4688931 0.80 TDP1 (0.49) SMN1; SMN2NPC1RAB9ALMNACTSK
SCHEMBL27230066 0.79 TSHR (0.54) SMN1; SMN2NPC1RAB9ALMNATDP1
SCHEMBL8583257 0.79 ALPI (0.47) NPC1RAB9ALMNAALDH1A1
SCHEMBL3425339 0.78 ATM (0.51) CTSKACECTSLCTSB
SCHEMBL4669847 0.78 EPHX1 (0.44) SMN1; SMN2NPC1RAB9AL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2454246-A2 SOLVATES OF DOCETAXEL Przedsiebiorstwo Produkcyjno-Wdrozeniowe (PL) 2012-05-23 EP claimed
WO-2010138010-A2 SOLVATES OF 4-ACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1,7β,10β-TRIHYDROXY-9-OXO-TAX-11 -EN- 13α-YL (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE Przedsiębiorstwo Produkcyjno-Wdrożeniowe (PL) 2010-12-02 WO claimed
EP-2247582-A2 CRYSTALLINE FORMS OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING SAME Aventis Pharma S.A. (FR) 2010-11-10 EP claimed
WO-2009115655-A2 CRYSTALLINE FORMS OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING SAME AVENTIS PHARMA S.A. (FR) 2009-09-24 WO claimed
EP-1667986-A1 DIMETHOXY DOCETAXEL ACETONE SOLVATE ET METHOD FOR THE PREPARATION THEREOF Aventis Pharma S.A. (FR) 2006-06-14 EP claimed
WO-2005028462-A1 DIMETHOXY DOCETAXEL ACETONE SOLVATE ET METHOD FOR THE PREPARATION THEREOF AVENTIS PHARMA S.A. (FR) 2005-03-31 WO claimed
EP-1176957-A1 METHOD FOR TREATING ABNORMAL CELL PROLIFERATION IN THE BRAIN Aventis Pharma S.A. (FR) 2002-02-06 EP claimed
WO-2000066113-A1 METHOD FOR TREATING ABNORMAL CELL PROLIFERATION IN THE BRAIN AVENTIS PHARMA S.A. (FR) 2000-11-09 WO claimed
EP-0876361-A1 4,10$g(b)-DIACETOXY-2$g(a)-BENZOYLOXY-5$g(b),20-EPOXY-1-HYDROXY-9-OXO-19-NOR-CYCLOPROPA G]TAX-11-ENE-13$g(a)-YL (2R,3S)-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DIHYDRATE, AND METHOD FOR PREPARING SAME Aventis Pharma S.A. (FR) 1998-11-11 EP claimed
WO-1997021695-A1 4,10β-DIACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1-HYDROXY-9-OXO-19-NOR-CYCLOPROPA[G]TAX-11-ENE-13α-YL (2R,3S)-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DIHYDRATE, AND METHOD FOR PREPARING SAME RHONE-POULENC RORER S.A. (FR) 1997-06-19 WO claimed
EP-3258931-A1 USE OF CABAZITAXEL IN THE TREATMENT OF PROSTATE CANCER Erasmus University Medical Center Rotterdam (NL) 2017-12-27 EP disclosed
WO-2016133387-A1 USE OF CABAZITAXEL IN THE TREATMENT OF PROSTATE CANCER ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) 2016-08-25 WO disclosed
WO-2015104417-A1 USE OF CABAZITAXEL FOR THE TREATMENT OF GASTRIC ADENOCARCINOMA AVENTIS PHARMA S.A. (FR) 2015-07-16 WO disclosed
WO-2015036507-A1 USE OF CABAZITAXEL IN PATIENTS WITH METASTATIC NSCLC PROGRESSING AFTER DOCETAXEL-BASED TREATMENT AVENTIS PHARMA S.A. (FR) 2015-03-19 WO disclosed
EP-2493466-A1 NOVEL ANTITUMORAL USE OF CABAZITAXEL Aventis Pharma S.A. (FR) 2012-09-05 EP disclosed
WO-2000066113-A1 METHOD FOR TREATING ABNORMAL CELL PROLIFERATION IN THE BRAIN AVENTIS PHARMA S.A. (FR) 2000-11-09 WO disclosed
EP-0876361-A1 4,10$g(b)-DIACETOXY-2$g(a)-BENZOYLOXY-5$g(b),20-EPOXY-1-HYDROXY-9-OXO-19-NOR-CYCLOPROPA G]TAX-11-ENE-13$g(a)-YL (2R,3S)-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DIHYDRATE, AND METHOD FOR PREPARING SAME Aventis Pharma S.A. (FR) 1998-11-11 EP disclosed
WO-1997021695-A1 4,10β-DIACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1-HYDROXY-9-OXO-19-NOR-CYCLOPROPA[G]TAX-11-ENE-13α-YL (2R,3S)-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DIHYDRATE, AND METHOD FOR PREPARING SAME RHONE-POULENC RORER S.A. (FR) 1997-06-19 WO disclosed
EP-0770070-A1 METHOD FOR PREPARING 4-ACETOXY-2ALPHA-BENZOYLOXY-5ALPHA,20-EPOXY-1,7BETA,10BETA-TRIHYDROXY-9-OXO-TAX-11-EN-13ALPHA-YL(2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE TRIHYDRATE Aventis Pharma S.A. (FR) 1997-05-02 EP disclosed
WO-1996001815-A1 METHOD FOR PREPARING 4-ACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1,7β,10β-TRIHYDROXY-9-OXO-TAX-11-EN-13α-YL(2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE TRIHYDRATE RHONE-POULENC RORER S.A. (FR) 1996-01-25 WO disclosed